Skip to main content
SpringerLink
Log in

Pituitary gland

New pathways in the pathogenesis of pituitary adenomas

  • News & Views
  • Published:

From Nature Reviews Endocrinology

View current issue Sign up to alerts

Acromegaly is caused by a growth-hormone-secreting pituitary adenoma. Mutations in the AIP gene predispose patients to young-onset pituitary adenomas that are resistant to somatostatin analogue therapy. Chalal et al. describe a potential mechanism by which AIP modulates responsiveness to somatostatin analogues and identify PLAGL1 as a potential modulator of therapeutic activity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Giustina, A. et al. A consensus on criteria for cure of acromegaly. J. Clin. Endocrinol. Metab. 95, 3141–3148 (2008).

    Article  Google Scholar 

  2. Sherlock, M. et al. Mortality in patients with pituitary disease. Endocr. Rev. 31, 301–342 (2010).

    Article  Google Scholar 

  3. Chalal, H. S. et al. Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway. J. Clin. Endocrinol. Metab. http://dx.doi.org/10.1210/jc.2012-1111.

  4. Lyons, J. et al. Two G protein oncogenes in human endocrine tumors. Science 249, 655–659 (1990).

    Article  CAS  Google Scholar 

  5. Vierimaa, O. et al. Pituitary adenoma predisposition caused by germline mutation in the AIP gene. Science 312, 1228–1230 (2006).

    Article  CAS  Google Scholar 

  6. Trivellin, G. & Korbonits, M. AIP and its interacting partners. J. Endocrinol. 210, 137–155 (2011).

    Article  CAS  Google Scholar 

  7. Cazabat, L. et al. Germline AIP mutations in apparently sporadic pituitary adenomas: prevalence in a prospective single-center cohort of 443 patients. J. Clin. Endocrinol. Metab. 97, E663–E670 (2012).

    Article  CAS  Google Scholar 

  8. Varrault, A. et al. Zac1 regulates an imprinted gene network critically involved in the control of embryonic growth. Dev. Cell 11, 711–722 (2006).

    Article  CAS  Google Scholar 

  9. Pagotto, U. et al. The expression of the antiproliferative gene ZAC is lost or highly reduced in nonfunctioning pituitary adenomas. Cancer Res. 60, 6794–6799 (2000).

    CAS  PubMed  Google Scholar 

  10. Theodoropoulou, M., Stalla, G. K. & Spengler, D. ZAC1 target genes and pituitary tumorigenesis. Mol. Cell. Endocrinol. 326, 60–65 (2010).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors wish to thank the Melvin Burkhardt Chair in Neurosurgical Oncology and the Karen Colina Wilson Research endowment in the Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center at the Cleveland Clinic.

Author information

Authors and Affiliations

  1. Department of Neurosurgery, MD Anderson Cancer Center, 1515 Holcombe Boulevard,, Houston, 77030, TX, USA

    Nicholas F. Marko

  2. The Neurological Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, 44195, OH, USA

    Robert J. Weil

Authors
  1. Nicholas F. Marko
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert J. Weil
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert J. Weil.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marko, N., Weil, R. New pathways in the pathogenesis of pituitary adenomas. Nat Rev Endocrinol 8, 572–573 (2012). https://doi.org/10.1038/nrendo.2012.143

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrendo.2012.143

  • Springer Nature Limited

This article is cited by

Search

Navigation